VANCOUVER, BC / ACCESSWIRE / January 14, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the “Company“ or “Mota Ventures“) is pleased to announce that its wholly owned subsidiary, Ihuana S.A.S (“Ihuana“), has completed its 2,000 square foot research and development facility in Guasca, Colombia (the “R&D Facility“). The purpose-built R&D Facility will be used for a seed registration program on Ihuana’s licensed land. This is a significant step, as it will allow Ihuana to begin the important process of registering the genetics of our high-CBD, low-THC strains of cannabis with the Colombian Agricultural Institute (Instituto Colombiano Agroprecuario, or ICA).
The R&D Facility is located on Ihuana’s fully-licensed 2.5-hectare agricultural site located in the Bogotá savannah region of Colombia. This area of Colombia has a fertile landscape that is world-renowned for its flower production and exportation. Cannabis plants thrive in the region’s mild and stable climate, consistent sunlight (about 12 hours per day year-round) and fertile soil. The Bogotá savannah is also an excellent region for cannabis cultivation due to its strong agricultural infrastructure, low labour costs and proximity to free trade zones and major airports for agricultural exportation.
The R&D Facility uses a market-leading agricultural cover film produced by Ginegar for use in greenhouses. Its unique thermal, mechanical and optical properties make it ideal for protecting crops and enhancing growth. The Company will use an existing structure on the property for cannabis propagation, cloning and drying.
The team at Mota Ventures is excited to announce the completion of the R&D Facility-a major step in the Company’s plan for the international distribution of CBD products. The R&D Facility will allow Ihuana to register up to ten strains of high-CBD, low-THC cannabis. Cultivating high-CBD strains of cannabis directly impacts the Company’s margins, as higher CBD content will result in a larger yield when extracted.
Joel Shacker, CEO of Mota, commented: “We have been working toward this milestone for some time and are pleased to announce that this puts us well ahead of schedule on our Colombian cultivation plan.”
About Mota Ventures Corp.
Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota Ventures is also seeking to acquire revenue-producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.
On Behalf of the Board of Directors of
MOTA VENTURES CORP.
“Joel Shacker”
Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, Chief Executive Officer at +1.604.423.4733 or by email at IR@motaventuresco.com or www.motaventuresco.com.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the registration of cannabis strains, the international distribution of CBD products and the creation or acquisition of CBD brands. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
SOURCE: Mota Ventures Corp.
View source version on accesswire.com:
https://www.accesswire.com/572924/Mota-Ventures-Completes-RD-Facility-in-Colombia
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…